Wybran J, Famaey J P, Appelboom T
J Rheumatol. 1981 Jul-Aug;8(4):643-6.
In an open study inosiplex, a new synthetic immunomodulatory drug, was given to 15 patients with rheumatoid arthritis (RA) 3 g daily until clinical improvement occurred and then tapered. Nine of 15 patients experienced clinical benefit evidenced by a reduction of morning stiffness, fewer tender joints, decreased proximal interphalangeal joint circumference, and decreased sedimentation rate and fibrinogen level. Three patients responded rapidly to inosiplex (in two weeks) and a clear cut improvement was noticed within 1 month by all the responders. Two patients showed an exacerbation of the disease. No toxic drug effect was noticed. Although the mode of action of inosiplex in RA appears unclear, its rapidly of action and high rate of response should encourage further study of its use in the treatment of RA.
在一项开放性研究中，给15例类风湿性关节炎（RA）患者服用一种新的合成免疫调节药物异丙肌苷，每日3克，直至出现临床改善，然后逐渐减量。15例患者中有9例出现临床获益，表现为晨僵减轻、压痛关节减少、近端指间关节周长减小、血沉和纤维蛋白原水平降低。3例患者对异丙肌苷反应迅速（两周内），所有有反应者在1个月内均有明显改善。2例患者病情加重。未观察到药物毒性作用。尽管异丙肌苷在类风湿性关节炎中的作用方式尚不清楚，但其起效迅速和高反应率应促使对其在类风湿性关节炎治疗中的应用进行进一步研究。
